- Correction
- Open access
- Published:
Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience
Journal of Pharmaceutical Health Care and Sciences volume 9, Article number: 16 (2023)
The Original Article was published on 10 January 2023
Correction to: J Pharm Health Care Sci9, 2 (2023)
After publication of the original article [1] the authors found an error in the analysis. According to the univariate logistic regression analysis findings summarized in original Table 1, the item “Type of chemotherapy (adjuvant chemotherapy vs. chemotherapy alone)” mentioned odds ratio (OR) of 2.93, with a 95% confidence interval (CI) of 1.29–6.62 and p-value of 0.010.
According to the statistical method used, this item should be included in multivariate analysis. However, the results for this clinical factor in the multivariate analysis were blank. The correct version of Table 1 is included in this correction article.
Accordingly, the corrected OR for younger age (< 55 years) related to pegfilgrastim-induced bone pain is 3.68 (95% CI 1.52–8.90, p = 0.003). Owing to the minimum alterations in OR and p-values in multivariate analysis, the authors believe that this correction does not significantly impact the study results.
References
Tsuboi S, Hayama T, Miura K, Uchiike A, Tsutsumi D, Yamauchi T, et al. Higher incidence of pegfilgrastim induced bone pain in younger patients receiving myelosuppressive chemotherapy: a realworld experience. J Pharm Heal Care Sci. 2023;9:1–5. https://doi.org/10.1186/s40780-022-00272-9.
Author information
Authors and Affiliations
Corresponding author
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s40780-022-00272-9.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Tsuboi, S., Hayama, T., Miura, K. et al. Correction to: Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience. J Pharm Health Care Sci 9, 16 (2023). https://doi.org/10.1186/s40780-023-00284-z
Published:
DOI: https://doi.org/10.1186/s40780-023-00284-z